Qelbree (Viloxazine Extended-Release) for ADHD
Qelbree is a non-stimulant ADHD medication that should be started at 100 mg daily in children (6-11 years), 200 mg daily in adolescents (12-17 years), and 200 mg daily in adults, with upward titration to optimal doses of 200-400 mg/day in children, 400-600 mg/day in adolescents, and 400-600 mg/day in adults based on response and tolerability. 1
Dosing Guidelines
Pediatric Dosing (Ages 6-17)
Children 6-11 years:
- Start: 100 mg once daily
- Target range: 200-400 mg/day
- Maximum: 400 mg/day
Adolescents 12-17 years:
- Start: 200 mg once daily
- Target range: 400-600 mg/day
- Maximum: 600 mg/day
Adult Dosing (Ages 18-65)
- Start: 200 mg once daily
- Target range: 400-600 mg/day (mean effective dose ~504 mg/day)
- Maximum: 600 mg/day 1, 2
Titration strategy: Recent dose-effect meta-analysis data shows that efficacy plateaus around 400 mg/day in children and adolescents, with no compelling evidence for routine use above FDA-licensed maxima 3. The optimal therapeutic window appears to be 200-400 mg (or 6-8 mg/kg) in pediatric patients 4.
Contraindications
Absolute contraindications:
- Concomitant use with MAOIs or within 14 days of MAOI discontinuation (risk of hypertensive crisis)
- Concomitant use with sensitive CYP1A2 substrates or those with narrow therapeutic range (e.g., theophylline, tizanidine) 1
Screen before initiating:
- Personal or family history of bipolar disorder, suicide, or depression (risk of activation of mania/hypomania and suicidal ideation) 1
- Active substance use disorder in adolescents (requires subspecialist consultation) 5
Monitoring Parameters
Baseline Assessment
- Blood pressure and heart rate
- Weight and height (calculate BMI percentile in pediatrics)
- Psychiatric history screening for bipolar disorder and suicidality
- Substance use screening in adolescents 1
Ongoing Monitoring
- Cardiovascular: Blood pressure and heart rate at each visit (Qelbree causes modest increases)
- Weight: Monitor regularly; expect minimal weight gain (0.2 kg) in younger children and slight weight loss (-0.2 kg) in adolescents over 6-8 weeks 1
- Suicidality: Use Columbia Suicide Severity Rating Scale (C-SSRS) at regular intervals 6
- Symptom response: ADHD Rating Scale assessments; therapeutic effects typically emerge within 2-3 weeks and plateau around weeks 4-6 4, 2
Drug Interaction Monitoring
- CYP1A2 substrates: Viloxazine is a strong CYP1A2 inhibitor; avoid coadministration or reduce doses of CYP1A2 substrates
- CYP2D6 and CYP3A4 substrates: Viloxazine is a weak inhibitor; monitor for adverse effects and adjust substrate doses as needed 1
Common Adverse Effects
Pediatric Patients (6-17 years)
Most common (≥5% and twice placebo rate):
- Somnolence: 16% (vs 4% placebo) - dose-related, highest at 400 mg
- Decreased appetite: 7% (vs 0.4% placebo)
- Headache: 11%
- Fatigue: 6% (vs 2% placebo)
- Nausea: 5% (vs 3% placebo)
- Vomiting: 4% (vs 2% placebo)
- Insomnia: 4% (vs 1% placebo)
- Irritability: 3% (vs 1% placebo) 1
Adult Patients
Most common (≥5% and twice placebo rate):
- Insomnia: 23% (vs 7% placebo)
- Headache: 17% (vs 7% placebo)
- Fatigue: 12% (vs 3% placebo)
- Nausea: 12% (vs 3% placebo)
- Decreased appetite: 10% (vs 3% placebo)
- Dry mouth: 10% (vs 2% placebo)
- Somnolence: 6% (vs 2% placebo)
- Constipation: 6% (vs 1% placebo) 1
Discontinuation rates: 3% in pediatrics and 9% in adults due to adverse events, with most events being mild to moderate 1, 6
Clinical Pearls and Pitfalls
Timing of effects: Symptom improvement begins within 2-3 weeks, with maximal benefit by weeks 4-6. The 100 mg dose shows more rapid decline in efficacy over time compared to 200-400 mg doses 4.
Somnolence management: This is the most common pediatric adverse effect (16%). Patients should not operate vehicles or machinery until they know how Qelbree affects them 1. Consider dosing adjustments or timing changes if problematic.
Avoid subtherapeutic dosing: The 2026 dose-effect meta-analysis emphasizes that suboptimal dosing is common in clinical practice and reduces treatment adherence. Clinicians should titrate upward from minimal doses when symptoms remain insufficiently controlled 3.
Adolescent driving safety: Given ADHD-related crash risks, ensure medication coverage during driving hours. Consider timing of once-daily dosing or adding short-acting coverage if needed 5.
Combination with stimulants: Real-world data suggests viloxazine ER may allow reduction in stimulant dosages and overall psychiatric medication burden when used concomitantly 7.
Long-term safety: Data extending to 72 months in pediatrics shows sustained efficacy with no new safety signals emerging over time 6.